3
Disclosures
Jan 8, 2026 — Mar 24, 2026
Date Range
GROWTH
Market Segment

Disclosures

DateTypeHeadlinePDF
Mar 24 Other GNI Group: Files NDA for Liver Fibrosis Drug F351 in China PDF
Mar 18 Admin GNI Group: Confirms F351 Receives Priority Review in China; Set to Submit Formal NDA Soon PDF
Mar 13 M&A Forecasts $400M-$632M Revenue Over Five Years for F351 Treatment PDF

Disclosure Types

Other: 1 Admin: 1 M&A: 1